UNIGE document Scientific Article
previous document  unige:9588  next document
add to browser collection

Empiric therapy of community-acquired pneumonia: a transatlantic controversy

Published in Revue médicale suisse. 2006, vol. 2, no. 50, p. 289-290, 292-294
Abstract North American and European guidelines for empiric antimicrobial therapy of community-acquired pneumonia differ. This stems from a different mechanism of pneumococcal resistance to macrolides, and a different perception of the need to cover atypical germs. For mild cases, two recent meta-analyses conclude that this coverage is not associated with any benefit. For more severe pneumonias, data are scarce and experts generally recommend wide coverage. Except for particular situations, the new fluoroquinolones should not represent the first-line therapy because of rapidly growing resistance to these antibiotics.
Keywords Ambulatory CareAnti-Bacterial AgentsAnti-Infective AgentsCommunity-Acquired InfectionsDrug Resistance, BacterialDrug Therapy, CombinationEuropeFluoroquinolonesHumansLactamsMacrolidesNorth AmericaPneumonia, BacterialPractice Guidelines as Topic
PMID: 16503046
Full text
This document has no fulltext available yet, but you can contact its author by using the form below.
(ISO format)
GARIN, Nicolas, NENDAZ, Mathieu. Empiric therapy of community-acquired pneumonia: a transatlantic controversy. In: Revue médicale suisse, 2006, vol. 2, n° 50, p. 289-290, 292-294. https://archive-ouverte.unige.ch/unige:9588

212 hits

0 download


Deposited on : 2010-07-12

Export document
Format :
Citation style :